Entering text into the input field will update the search result below

Akcea out-licenses antisense candidate to Pfizer for up to $1.5B

  • Ionis Pharmaceuticals (NASDAQ:IONS) affiliate Akcea Therapeutics (NASDAQ:AKCA) inks an agreement with Pfizer (NYSE:PFE) for global rights to antisense drug AKCEA-ANGPTL3-Lrx for certain cardiovascular and metabolic diseases.
  • Under the terms of the deal, Akcea and Ionis will receive $250M upfront, divided equally, up to $1.3B in milestones and tiered double-digit royalties on net sales. Akcea will settle its $125M obligation to Ionis via common stock instead of cash.
  • Pfizer will be responsible for all development and regulatory activities beyond the ongoing Phase 2 trial.
  • Akcea has the right to participate in certain commercialization activities in the U.S. and selected other markets based on predefined terms and criteria.
  • AKCEA-ANGPTL3-Lrx is designed to reduce the production of a protein called angiopoietin-like 3, a key regulator of a range of lipid and metabolic pathways. The absence of the protein is associated with reduced risk of insulin resistance and diabetes.
  • Update: The agreement closed on November 19.

Recommended For You

Related Stocks

SymbolLast Price% Chg
PFE
--
IONS
--
AKCA
--